Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px
Document › Details

MolMed S.p.A.. (6/7/16). "Press Release: MolMed and Oxford BioMedica Reviewed and Expanded the Existing License Agreements’ Framework". Milan.

Organisations Organisation MolMed S.p.A. (MLMD.MI)
  Organisation 2 Oxford BioMedica plc (LSE: OXB)
  Group Oxford BioMedica (Group)
Products Product LentiVector® technology
  Product 2 Zalmoxis®
Index term Index term MolMed–Oxford BioMedica: LentiVector technology, 201606– licenese non-excl for manufacturing + developm replacing 2004 agreement
     


MolMed S.p.A. (MLM.MI) and Oxford BioMedica plc (“Oxford BioMedica”) (LSE: OXB), today signed a new non-exclusive licence agreement concerning lentiviral vector technology and, considering recent expiration of relevant patents, terminated the existing exclusive licence agreement on retroviral patents.

By means of the new licence agreement, Oxford BioMedica grants to MolMed a non-exclusive licence under its LentiVector® platform technology for manufacturing and development services.

At the same time, the parties terminated the agreement dated 10 December 2004 under which Oxford BioMedica granted MolMed a world-wide, exclusive licence on development and commercialisation of certain products in the field of genetically modified T lymphocytes transduced with retroviral vectors used in research and ex vivo gene therapy, including Zalmoxis® (TK). As a result of this agreement settlement, MolMed owes no outstanding royalties to Oxford BioMedica while keep using the above mentioned technology, in the ongoing development and potential commercialization of Zalmoxis® (TK).


This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14.5.1999, as subsequently amended.


About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, currently in Phase III in high-risk acute leukaemia and under evaluation by EMA for a Conditional Marketing Authorization; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6, an immuno-gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed has its headquarters at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and a local unit at OpenZone, in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).


For further information

Laura Villa
Investor Relations & Communication
Director
phone: +39 02 21277.205
e-mail: investor.relations@molmed.com

Press agent
Federico Ferrari
SEC Relazioni Pubbliche e Istituzionali s.r.l.
phone: +39 02 6249991 – mobile +39 347 6456873
e-mail: ferrari@secrp.it


DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are
based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties,
including scientific, business, economic and financial factors, which could cause actual results to differ materially from
those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking
statements or adapt them to future events or developments. This document does not constitute an offer or invitation to
subscribe or purchase any securities of MolMed S.p.A.

   
Record changed: 2016-06-27

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px

More documents for MolMed S.p.A. (MLMD.MI)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px